Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT-12 adjuvant bempegaldesleukin plus nivolumab versus nivolumab in resected high-risk melanoma
MOH_2020-10-18_009411Phase 3Not yet recruiting
- Sponsor
- Nektar Therapeutics
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) comparing Bempegaldesleukin plus nivolumab with Nivolumab monotherapy (2 arms). Primary endpoint: Primary endpoint not provided. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on MOH_2020-10-18_009411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-18_009411.